12:43 PM EDT, 07/01/2024 (MT Newswires) -- Merus (MRUS) said it has appointed Fabian Zohren as its chief medical officer, effective Monday.

Zohren succeeds Andrew Joe, who will step down and continue as a consultant for the next three months, the company said.

The firm said Zohren most recently served as chief medical officer at ImmunoGen, which was acquired by AbbVie (ABBV) recently.

Merus also said Hui Liu, chief business officer and head of Merus US, is leaving the company, and it is looking for a replacement.

Shares of Merus were down more than 7% in recent trading.

Price: 55.00, Change: -4.17, Percent Change: -7.05